

DRUG PRIOR AUTHORIZATION COMMITTEE
September 17, 2009
TENTATIVE AGENDA

10:00 - 10:05	Welcome, Announcements and Introductions	Henry Petry, Chairman
10:05 - 10:15	Minutes Review	Discussion/ Approval
10:15- 11:15	Pharmacy Program/ Budget Update	George Oestreich/ Andrew Haslag
11:15 - 11:20	DUR Update	Tisha McGowan

Old Business

11:20 – 11:30	Implementation Schedule (Criteria for Previously Approved Clinical Edits, Step Therapies and PA's)	Rhonda Driver/ Jay Bryant Wimp
---------------	--	-----------------------------------

New Business

11:30 – 11:45	a. Proposed Actions- New Drug/Product Reviews (See website and Attached Summary)	Rhonda Driver/ Jay Bryant Wimp
	i. Open Access	
	ii. Clinical Edit/Step Therapy	
	iii. PDL Products	
	iv. Prior Authorization	
	<ul style="list-style-type: none">• Discussion• Public Hearing• Decision	
	b. Clinical Edits	
	i. Synagis Clinical Edit Changes	
	<ul style="list-style-type: none">• Discussion• Public Hearing• Decision	

11:45:1:00

- | | |
|--|--|
| a. Preferred Drug List (PDL) | |
| i. Ace Inhibitors | |
| <ul style="list-style-type: none">• Discussion• Public Hearing• Decision | |
| ii. Ace Inhibitor/Diuretic Combination | |
| <ul style="list-style-type: none">• Discussion• Public Hearing• Decision | |
| iii. Ace Inhibitor/Calcium Channel Blocker Combination | |
| <ul style="list-style-type: none">• Discussion• Public Hearing• Decision | |
| iv. Alpha-Glucosidase Inhibitors | |
| <ul style="list-style-type: none">• Discussion• Public Hearing• Decision | |
| v. Alzheimer's Agents | |
| <ul style="list-style-type: none">• Discussion• Public Hearing• Decision | |
| vi. Angiotensin Receptor Blocker | |
| <ul style="list-style-type: none">• Discussion• Public Hearing• Decision | |

- vii. **Angiotensin Receptor Blocker/Diuretic Combination**
 - Discussion
 - Public Hearing
 - Decision
- viii. **Antidiabetic Combination Agents**
 - Discussion
 - Public Hearing
 - Decision
- ix. **Biguanides**
 - Discussion
 - Public Hearing
 - Decision
- x. **Bone Ossification Suppression Agents/Calcitonins**
 - Discussion
 - Public Hearing
 - Decision
- xi. **Direct Renin Inhibitor**
 - Discussion
 - Public Hearing
 - Decision
- xii. **Direct Renin Inhibitor Combinations**
 - Discussion
 - Public Hearing
 - Decision
- xiii. **Electrolyte Depleters**
 - Discussion
 - Public Hearing
 - Decision
- xiv. **Herpes Antivirals**
 - Discussion
 - Public Hearing
 - Decision
- xv. **Immunomodulators/RA Agents (DMARDs)**
 - Discussion
 - Public Hearing
 - Decision
- xvi. **Leukotriene Modifiers**
 - Discussion
 - Public Hearing
 - Decision
- xvii. **Lipotropics-Niacin Preparations**
 - Discussion
 - Public Hearing
 - Decision
- xviii. **Low Sedating Antihistamines**
 - Discussion
 - Public Hearing
 - Decision
- xix. **Low Sedating Antihistamine/Decongestant Combinations**
 - Discussion
 - Public Hearing
 - Decision
- xx. **Macrolides Adult/Pediatric**
 - Discussion
 - Public Hearing
 - Decision
- xxi. **Meglitinides**
 - Discussion
 - Public Hearing
 - Decision

- xxii. **Multiple Sclerosis Agents**
 - Discussion
 - Public Hearing
 - Decision
- xxiii. **Narcotics: Long Acting**
 - Discussion
 - Public Hearing
 - Decision
- xxiv. **Nasal Steroids**
 - Discussion
 - Public Hearing
 - Decision
- xxv. **Ophthalmic Antihistamines**
 - Discussion
 - Public Hearing
 - Decision
- xxvi. **Ophthalmic Mast Cell Stabilizers**
 - Discussion
 - Public Hearing
 - Decision
- xxvii. **Ophthalmic Quinolones**
 - Discussion
 - Public Hearing
 - Decision
- xxviii. **Ophthalmic Prostaglandin Agonists**
 - Discussion
 - Public Hearing
 - Decision
- xxix. **Oral Pulmonary Hypertension Agents**
 - Discussion
 - Public Hearing
 - Decision
- xxx. **Otic Quinolones**
 - Discussion
 - Public Hearing
 - Decision
- xxxi. **Quinolones-Systemic**
 - Discussion
 - Public Hearing
 - Decision
- xxxii. **2nd Generation Sulfonylureas**
 - Discussion
 - Public Hearing
 - Decision
- xxxiii. **Serotonin Receptor Agonists (Triptans)**
 - Discussion
 - Public Hearing
 - Decision
- xxxiv. **Thiazolidinediones**
 - Discussion
 - Public Hearing
 - Decision
- xxxv. **Topical Agents for Psoriasis**
 - Discussion
 - Public Hearing
 - Decision
- xxxvi. **Topical Retinols**
 - Discussion
 - Public Hearing
 - Decision

xxxvii. Ulcerative Colitis Agents/Oral and Rectal

- Discussion
- Public Hearing
- Decision

xxxviii. Vaginal Antibiotics

- Discussion
- Public Hearing
- Decision

xxxix. Intranasal Antihistamines

- Discussion
- Public Hearing
- Decision

b. Preferred Drug List

i. Process Discussion

ii. Therapeutic classes/To be announced at meeting.

1:00

LUNCH

1:15-1:30

Program Utilization Information

Rhonda Driver/
Jay Bryant Wimp

1:30-1:50

Other Business

- *“Top 25” Drugs by Cost*
- *Clinical Edit Summary Report*
- *Call Center Statistics*

*Informal comments will be accepted from members of the audience at various points in the agenda.
Times noted are approximate, Agenda may move more quickly*

Executive Session

1:50-1:55

Minutes Review

Discussion/Approval

1:55-2:30

Case Reviews

Jenna Twehus

NEXT MEETING: December 18, 2008 – 205 Jefferson Street, 10th Floor